Nordic registry study finds no pancreatic cancer signal with semaglutide
The regulator-mandated safety study tracked 97,464 semaglutide users against matched new users of sulfonylureas, SGLT-2 inhibitors or insulin.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 28 18:00 ETSource: Medical Xpress
The wire
- 01Presented at EASD in Milan, the Denmark, Sweden and Norway cohort found 131 pancreatic cancer cases among semaglutide users versus 123 among active comparators, with similar incidence rates.
- 02Regulators requested the post-authorization study at semaglutide approval after rodent findings and adverse-event reports raised a pancreatic cancer hypothesis.
- 03Mean follow-up after the one-year lag was only 1.40 to 1.85 years, too short to rule out longer-latency malignancy; the work was presented at a meeting.
From the source
Read at medicalxpress.comRegulator-mandated study finds no link between semaglutide use and pancreatic cancer
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
